Guide to Implementation - WHO
approach as key to protect the patient, the health-care worker and the health-care environment against the spread of pathogens and thus reduce HCAI. This approach encourages health-care workers to clean their hands (1) before touching a patient, (2) before clean/aseptic procedures, (3) after body fluid exposure/risk, (4) after touching
Download Guide to Implementation - WHO
Information
Domain:
Source:
Link to this page:
Documents from same domain
INVESTING IN HEALTH FOR ECONOMIC …
www.who.int2 INVESTING IN HEALTH FOR ECONOMIC DEVELOPMENT Report by the Mexican Commission on Macroeconomics and health 3 The …
WHO GOOD PRACTICES FOR PHARMACEUTICAL …
www.who.intworking document qas/09.297/rev.2 page 2 schedule for the proposed adoption process of document qas/09.297/rev.2: who good practices for pharmaceutical microbiology laboratories
NORMES ET STANDARDS EN INFRASTRUCTURES …
www.who.intnormes et standards en infrastructures et equipements du centre de sante et de promotion sociale, du centre medical avec antenne chirurgicale et du …
Heterotrophic Plate Count Measurement in …
www.who.intWorld Health Organization Sustainable Development and Healthy Environments Heterotrophic Plate Count Measurement in Drinking Water Safety Management
Annex 3 WHO good manufacturing practices for ...
www.who.int96 Introduction The fi rst WHO draft text on good manufacturing practices (GMP) was prepared in 1967 by a group of consultants at the request of the Twentieth
Annex 5 WHO good distribution practices for …
www.who.int236 1. Introduction Distribution is an important activity in the integrated supply-chain management of pharmaceutical products. Various people and entities are
Annex 2 WHO good practices for pharmaceutical …
www.who.int71 Introduction and scope of document Pharmaceutical microbiology laboratories may be involved in: — sterility testing; — detection, isolation, enumeration and identifi cation of microorganisms
LABORATORY BIOSAFETY MANUAL - WHO
www.who.intinterim guidelines WHO/CDS/CSR/LYO/2003.4 LABORATORY BIOSAFETY MANUAL SECOND EDITION (REVISED) WORLD HEALTH ORGANIZATION Geneva 2003
Mycobacteriology Laboratory Manual - WHO
www.who.intMycobacteriology Laboratory Manual ii Edita Pimkina, Infectious Diseases and Tuberculosis Hospital Affi liate of Public institution …
Laboratory Guidelines for enumerating CD4 T …
www.who.intSEA-HLM-392 Distribution: Limited Laboratory Guidelines for enumerating CD4 T Lymphocytes in the context of HIV/AIDS Regional Office for South-East Asia
Related documents
<1151> PHARMACEUTICAL DOSAGE FORMS
www.drugfuture.com“Quality” is used herein as suitable shorthand for all such compendial require-the Guide to General Chapters, Charts 4–8 and 10–13. ments. This approach also is consistent with U.S. and FDA participation in theAn appropriate manufacturing process and testing regi-International Conference on Harmonization (ICH). The ICH guideline on spec-
Compilation of QRD decisions on stylistic matters in ...
www.ema.europa.euThe approach varies across languages, so acronyms/abbreviations ... of excipients in the product ... Any additional concise information on the disease (e.g. symptoms and signs of the disease, general precautions and appropriate treatment or other measures to take) could be included in section 1 or at the end of the ...
active substance, excipient and primary container ...
www.ema.europa.euGeneral requirements.....5 4.1. Requirements for the manufacture of sterile medicinal products and sterile components6 ... sterile excipients and sterile primary containers (referred to as container in this guideline) ... justified under a risk-based approach. For veterinary cell based novel therapies, cross reference is ...
232 ELEMENTAL IMPURITIES—LIMITS
www.usp.orgThis general chapter specifies limits for the amounts of elemental impurities in drug products. Elemental impurities include catalysts and environmental contaminants that may be present in drug substances, excipients, or drug products. These impuri-
467 RESIDUAL SOLVENTS - USP-NF
www.uspnf.comSep 27, 2019 · All solvents included in this general chapter are listed in Appendix 1. Those solvents that show toxicity of special concern or carcinogenicity, and/or atmospheric ozone-depletion effects (Class 1, see Table 2), should be avoided in the production of drug substances, dietary supplement ingredients, excipients, pharmaceutical drug products,
STABILITY TESTING OF ACTIVE SUBSTANCES AND …
www.who.int2.1.1 General Information on the stability of the active substance is an integral part of the systematic approach to stability evaluation. For active substances not described in an official pharmacopoeial monograph, stability studies are required. For active substances described in